The Value of 18F-DOPA PET-CT in Patients with Medullary Thyroid Carcinoma: Comparison with 18F-FDG PET-CT

Overview

Journal Eur Radiol

Specialty Radiology

Date 2009 Jan 22

PMID 19156423

Citations 34

Authors

Mohsen Beheshti

Sigrid Pocher

Reza Vali

Peter Waldenberger

Gabriele Broinger

Michael Nader

Susanne Kohlfurst

Christian Pirich

Henning Dralle

Werner Langsteger

Affiliations

Soon will be listed here.

Abstract

The purpose of this prospective study was to compare the value of DOPA PET-CT with FDG PET-CT in the detection of malignant lesions in patients with medullary thyroid carcinoma (MTC). Twenty-six consecutive patients (10 men, 16 women, mean age 59 +/- 14 years) with elevated calcitonin levels were evaluated in this prospective study. DOPA and FDG PET-CT modalities were performed within a maximum of 4 weeks (median 7 days) in all patients. The data were evaluated on a patient- and lesion-based analysis. The final diagnosis of positive PET lesions was based on histopathological findings and/or imaging follow-up studies (i.e., DOPA and/or FDG PET-CT) for at least 6 months (range 6-24 months). In 21 (21/26) patients at least one malignant lesion was detected by DOPA PET, while only 15 (15/26) patients showed abnormal FDG uptake. DOPA PET provided important additional information in the follow-up assessment in seven (27%) patients which changed the therapeutic management. The patient-based analysis of our data demonstrated a sensitivity of 81% for DOPA PET versus 58% for FDG PET, respectively. In four (4/26) postoperative patients DOPA and FDG PET-CT studies were negative in spite of elevated serum calcitonin and CEA levels as well as abnormal pentagastrin tests. Overall 59 pathological lesions with abnormal tracer uptake were seen on DOPA and/or FDG PET studies. In the final diagnosis 53 lesions proved to be malignant. DOPA PET correctly detected 94% (50/53) of malignant lesions, whereas only 62% (33/53) of malignant lesions were detected with FDG PET. DOPA PET-CT showed superior results to FDG PET-CT in the preoperative and follow-up assessment of MTC patients. Therefore, we recommend DOPA PET-CT as a one-stop diagnostic procedure to provide both functional and morphological data in order to select those patients who may benefit from (re-)operation with curative intent as well as guiding further surgical procedures.

Citing Articles

Sensitivities evaluation of five radiopharmaceuticals in four common medullary thyroid carcinoma metastatic sites on PET/CT: a network meta-analysis and systematic review.

Li P, Zhang Y, Xu T, Zhu J, Wei T, Zhao W Nucl Med Commun. 2023; 44(12):1114-1125.

PMID: 37769014 PMC: 10631508. DOI: 10.1097/MNM.0000000000001773.

Molecular imaging and related therapeutic options for medullary thyroid carcinoma: state of the art and future opportunities.

Imperiale A, Berti V, Burgy M, Cazzato R, Piccardo A, Treglia G Rev Endocr Metab Disord. 2023; 25(1):187-202.

PMID: 37715050 DOI: 10.1007/s11154-023-09836-y.

Next-Generation Molecular Imaging of Thyroid Cancer.

Jin Y, Liu B, Younis M, Huang G, Liu J, Cai W Cancers (Basel). 2021; 13(13).

PMID: 34202358 PMC: 8268517. DOI: 10.3390/cancers13133188.

Evaluation of F-18 DOPA PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: comparison with GA-68 DOTA-TATE PET/CT.

Asa S, Sonmezoglu K, Uslu-Besli L, Sahin O, Karayel E, Pehlivanoglu H Ann Nucl Med. 2021; 35(8):900-915.

PMID: 33993425 DOI: 10.1007/s12149-021-01627-2.

Amino Acid Transporters as Potential Therapeutic Targets in Thyroid Cancer.

Enomoto K, Hotomi M Endocrinol Metab (Seoul). 2020; 35(2):227-236.

PMID: 32615707 PMC: 7386108. DOI: 10.3803/EnM.2020.35.2.227.

References

Wang Q, Takashima S, Fukuda H, Takayama F, Kobayashi S, Sone S . Detection of medullary thyroid carcinoma and regional lymph node metastases by magnetic resonance imaging. Arch Otolaryngol Head Neck Surg. 1999; 125(8):842-8. DOI: 10.1001/archotol.125.8.842. View

Ong S, Schoder H, Patel S, Tabangay-Lim I, Doddamane I, Gonen M . Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med. 2007; 48(4):501-7. DOI: 10.2967/jnumed.106.036681. View

Gdeedo A, Van Schil P, Corthouts B, Van Mieghem F, Van Meerbeeck J, Marck E . Comparison of imaging TNM [(i)TNM] and pathological TNM [pTNM] in staging of bronchogenic carcinoma. Eur J Cardiothorac Surg. 1997; 12(2):224-7. DOI: 10.1016/s1010-7940(97)00084-5. View

Tung W, Vesely T, Moley J . Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery. 1995; 118(6):1024-9; discussion 1029-30. DOI: 10.1016/s0039-6060(05)80109-6. View

Musholt T, Musholt P, Dehdashti F, Moley J . Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study. Surgery. 1998; 122(6):1049-60; discussion 1060-1. DOI: 10.1016/s0039-6060(97)90208-7. View

Iten F, Muller B, Schindler C, Rochlitz C, Oertli D, Macke H . Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res. 2007; 13(22 Pt 1):6696-702. DOI: 10.1158/1078-0432.CCR-07-0935. View

Ugur O, Kostakglu L, Guler N, Caner B, Uysal U, Elahi N . Comparison of 99mTc(V)-DMSA, 201Tl and 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid. Eur J Nucl Med. 1996; 23(10):1367-71. DOI: 10.1007/BF01367593. View

Li S, Beheshti M . The radionuclide molecular imaging and therapy of neuroendocrine tumors. Curr Cancer Drug Targets. 2005; 5(2):139-48. DOI: 10.2174/1568009053202054. View

Beuthien-Baumann B, Strumpf A, Zessin J, Bredow J, Kotzerke J . Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2007; 34(10):1604-9. DOI: 10.1007/s00259-007-0425-2. View

10.

Diehl M, Risse J, Brandt-Mainz K, Dietlein M, Bohuslavizki K, Matheja P . Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med. 2001; 28(11):1671-6. DOI: 10.1007/s002590100614. View

11.

Guerra U, Pizzocaro C, Terzi A, Giubbini R, Bestagno M . The use of 99mTc(V)DMSA as imaging for the medullary thyroid carcinoma (MTC). J Nucl Med Allied Sci. 1988; 32(4):242-7. View

12.

Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven T, Roeher H . Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med. 2003; 349(16):1517-25. DOI: 10.1056/NEJMoa012915. View

13.

Modigliani E, Cohen R, Campos J, Conte-Devolx B, Maes B, Boneu A . Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol (Oxf). 1998; 48(3):265-73. DOI: 10.1046/j.1365-2265.1998.00392.x. View

14.

Raue F, Kotzerke J, REINWEIN D, Schroder S, Roher H, DECKART H . Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Investig. 1993; 71(1):7-12. DOI: 10.1007/BF00210956. View

15.

de Groot J, Links T, Jager P, Kahraman T, Plukker J . Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol. 2004; 11(8):786-94. DOI: 10.1245/ASO.2004.10.015. View

16.

Adams S, Baum R, Rink T, Usadel K, Hor G . Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med. 1998; 25(1):79-83. DOI: 10.1007/s002590050197. View

17.

Cohen E, Shaha A, Rinaldo A, Devaney K, Ferlito A . Medullary thyroid carcinoma. Acta Otolaryngol. 2004; 124(5):544-57. DOI: 10.1080/00016480310015704. View

18.

Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E . 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001; 28(1):64-71. DOI: 10.1007/s002590000404. View

19.

Bollen E, Goei R, Versteege C, Engelshove H, Lamers R . Interobserver variability and accuracy of computed tomographic assessment of nodal status in lung cancer. Ann Thorac Surg. 1994; 58(1):158-62. DOI: 10.1016/0003-4975(94)91091-x. View

20.

Bockisch A, Brandt-Mainz K, Gorges R, Muller S, Stattaus J, Antoch G . Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner. Acta Med Austriaca. 2003; 30(1):22-5. DOI: 10.1046/j.1563-2571.2003.02045.x. View